Opportunities in the Global Refractory Follicular Lymphoma Diagnostics Market include the growing need for MRD monitoring and ...
Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...
The Global Mantle Cell Lymphoma Market offers significant growth potential driven by an aging population increasing cancer ...
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...
IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma ...
Hollie Thursby, 28, detailed the painful side effect she experienced when drinking a glass of wine ...
Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune ...
Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...
Novartis intends to submit ianalumab for regulatory approval globally in early 2026.
Michael Wang, MD, highlights standout translational studies from ASH 2025 that advance understanding of prognosis and drug ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
Cancer survivors' follow-up frequency depends on cancer type, treatment response, and individual factors, including insurance coverage. Recent CT results showed slightly increased mesenteric nodes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results